碳青霉烯类抗菌药物管理效果研究
|
摘要
目的评价抗菌药物管理(AMS)对碳青霉烯类抗菌药物使用管理的效果。方法回顾性分析医院2016年至2017年实施AMS前后出院患者碳青霉烯类抗菌药物用药频度(DDDs)、使用强度(AUD)、限定日费用(DDC)、使用金额等的变化。结果实施AMS后,碳青霉烯类药物使用量呈持续下降趋势且总抗菌药物DDDs和AUD总体有下降趋势,总抗菌药物、碳青霉烯类抗菌药物使用金额和DDC呈总体下降趋势。结论实施AMS可显著降低碳青霉烯类药物DDDs和AUD,效果显著。
Objective To evaluate the effect of antimicrobial stewardship( AMS) on the use and management of carbapenem antibi-otics. Methods The changes of DDDs,AUD,DDC and the cost of carbapenem antibiotics used by discharged patients before and afterthe implementation of AMS from 2016 to 2017 were retrospectively analyzed. Results After the implementation of AMS,the use of car-bapenem antibiotics showed a continuous downward trend, and the DDDs, AUD of the total antibiotics had a downward trend. The costand DDC of total antibiotics and carbapenem antibiotics showed a general downward trend. Conclusion The implementation of AMS cansignificantly reduce the DDDs and AUD of carbapenem antibiotics,and the effect is remarkable.
Objective To evaluate the effect of antimicrobial stewardship( AMS) on the use and management of carbapenem antibi-otics. Methods The changes of DDDs,AUD,DDC and the cost of carbapenem antibiotics used by discharged patients before and afterthe implementation of AMS from 2016 to 2017 were retrospectively analyzed. Results After the implementation of AMS,the use of car-bapenem antibiotics showed a continuous downward trend, and the DDDs, AUD of the total antibiotics had a downward trend. The costand DDC of total antibiotics and carbapenem antibiotics showed a general downward trend. Conclusion The implementation of AMS cansignificantly reduce the DDDs and AUD of carbapenem antibiotics,and the effect is remarkable.
引文
[1]张楠,陆红柳,杨慧鹃,等.某院碳青霉烯类抗菌药物的临床应用调查与用药合理性评估[J].中国药房,2016,27(29):4047-4050.
[2] GHORBANI-DALINI S,KARGAR M,DOOSTI A,et al. Molec-ular Epidemiology of ESBL Genes and Multi-Drug Resistance inDiarrheagenic Escherichia coli Strains Isolated from Adults inIran[J]. Iran J Pharm Res,2015,14(4):1257-1262.
[3] EPSTEIN L,HUNTER JC,ARWADY MA,et al. New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coliassociated with exposure to duodenoscopes[J]. JAMA,2014,312(14):1447-1455.
[4] FALAGAS ME,TANSARLI GS,KARAGEORGOPOULOS DE,etal. Deaths attributable to carbapenem-resistant Enterobacteria-ceae infections[J]. Emerg Infect Dis,2014,20(7):1170-1175.
[5] World Health Organization. Guidelines for the prevention andcontrol of carbapenem-resistant Enterobacteriaceae,Acinetobacterbaumannii and Pseudomonas aeruginosa in health care facilities[EB/OL].(2018-02-23)[2018-05-08]. http://www. who.int/infection-prevention/publications/guidelines-cre/en.
[6] World Health Organization. WHO Collaborating Centre for DrugStatistics and Methodology[EB/OL].(2016-12-19)[2018-05-08]. https://www. whocc. no/atc_ddd_index.
[7] MONNET DL. Measuring antimicrobial use:the way forward[J].Clinical Infectious Diseases An Official Publication of the Infec-tious Diseases Society of America,2007,44(5):671-673.
[8]陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:34-91.
[9]屈晓远,尹畅,董盼盼,等.三级甲等医院抗菌药物管理政策干预影响[J].中国公共卫生,2017,33(7):1038-1044.
[2] GHORBANI-DALINI S,KARGAR M,DOOSTI A,et al. Molec-ular Epidemiology of ESBL Genes and Multi-Drug Resistance inDiarrheagenic Escherichia coli Strains Isolated from Adults inIran[J]. Iran J Pharm Res,2015,14(4):1257-1262.
[3] EPSTEIN L,HUNTER JC,ARWADY MA,et al. New Delhi metallo-β-lactamase-producing carbapenem-resistant Escherichia coliassociated with exposure to duodenoscopes[J]. JAMA,2014,312(14):1447-1455.
[4] FALAGAS ME,TANSARLI GS,KARAGEORGOPOULOS DE,etal. Deaths attributable to carbapenem-resistant Enterobacteria-ceae infections[J]. Emerg Infect Dis,2014,20(7):1170-1175.
[5] World Health Organization. Guidelines for the prevention andcontrol of carbapenem-resistant Enterobacteriaceae,Acinetobacterbaumannii and Pseudomonas aeruginosa in health care facilities[EB/OL].(2018-02-23)[2018-05-08]. http://www. who.int/infection-prevention/publications/guidelines-cre/en.
[6] World Health Organization. WHO Collaborating Centre for DrugStatistics and Methodology[EB/OL].(2016-12-19)[2018-05-08]. https://www. whocc. no/atc_ddd_index.
[7] MONNET DL. Measuring antimicrobial use:the way forward[J].Clinical Infectious Diseases An Official Publication of the Infec-tious Diseases Society of America,2007,44(5):671-673.
[8]陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:34-91.
[9]屈晓远,尹畅,董盼盼,等.三级甲等医院抗菌药物管理政策干预影响[J].中国公共卫生,2017,33(7):1038-1044.